adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Company profile
Ticker
ADMA
Exchange
Website
CEO
Adam S. Grossman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
R&R ACQUISITION VI, INC
SEC CIK
Corporate docs
Subsidiaries
ADMA BioCenters Georgia Inc. • ADMA Plasma Biologics, Inc. • ADMA BioManufacturing, LLC ...
ADMA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEFA14A
Additional proxy soliciting materials
15 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life
11 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
ADMA Biologics Announces CFO Transition
28 Feb 24
8-K
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
28 Feb 24
8-K
Other Events
21 Feb 24
Transcripts
ADMA
Earnings call transcript
2023 Q4
28 Feb 24
ADMA
Earnings call transcript
2023 Q3
8 Nov 23
ADMA
Earnings call transcript
2023 Q2
9 Aug 23
ADMA
Earnings call transcript
2023 Q1
10 May 23
ADMA
Earnings call transcript
2022 Q4
23 Mar 23
ADMA
Earnings call transcript
2022 Q3
10 Nov 22
ADMA
Earnings call transcript
2022 Q2
11 Aug 22
ADMA
Earnings call transcript
2022 Q1
11 May 22
ADMA
Earnings call transcript
2021 Q4
24 Mar 22
ADMA
Earnings call transcript
2021 Q3
11 Nov 21
Latest ownership filings
4
Kaitlin M. Kestenberg-Messina
2 Apr 24
4
Adam S Grossman
2 Apr 24
3
Kaitlin M. Kestenberg-Messina
2 Apr 24
4
STEVE ELMS
19 Mar 24
4
STEVE ELMS
15 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
SC 13G/A
TEACHERS ADVISORS, LLC
11 Mar 24
SC 13G/A
TIAA CREF INVESTMENT MANAGEMENT LLC
11 Mar 24
SC 13G/A
Nuveen Asset Management, LLC
11 Mar 24
4
BRIAN LENZ
8 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 74.16 mm | 74.16 mm | 74.16 mm | 74.16 mm | 74.16 mm | 74.16 mm |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) | 1.35 mm |
Cash used (since last report) | n/a | n/a | n/a | n/a | n/a | 8.93 mm |
Cash remaining | n/a | n/a | n/a | n/a | n/a | 65.22 mm |
Runway (months of cash) | n/a | n/a | n/a | n/a | n/a | 48.4 |
Institutional ownership, Q3 2023
33.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 398 |
Opened positions | 56 |
Closed positions | 41 |
Increased positions | 137 |
Reduced positions | 143 |
13F shares | Current |
---|---|
Total value | 3.56 tn |
Total shares | 77.79 mm |
Total puts | 504.20 k |
Total calls | 459.60 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
NWQ Investment Management | 10.61 mm | $14.96 mm |
BLK Blackrock | 9.01 mm | $519.14 bn |
Vanguard | 7.61 mm | $438.71 bn |
College Retirement Equities Fund | 4.28 mm | $149.22 mm |
FMR | 2.69 mm | $155.10 bn |
Dimensional Fund Advisors | 2.60 mm | $149.65 bn |
STT State Street | 2.34 mm | $135.04 bn |
Fisher Asset Management | 2.09 mm | $120.30 bn |
IVZ Invesco | 1.56 mm | $89.75 bn |
Fuller & Thaler Asset Management | 1.41 mm | $81.42 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Kaitlin M. Kestenberg-Messina | Common Stock | Grant | Acquire A | No | No | 0 | 192,320 | 0.00 | 304,510 |
1 Apr 24 | Kaitlin M. Kestenberg-Messina | Stock Option Common Stock | Grant | Acquire A | No | No | 6.54 | 300,328 | 1.96 mm | 300,328 |
31 Mar 24 | Kaitlin M. Kestenberg-Messina | Common Stock | Payment of exercise | Dispose F | No | No | 6.6 | 2,085 | 13.76 k | 112,190 |
31 Mar 24 | Grossman Adam S | Common Stock | Payment of exercise | Dispose F | No | No | 6.6 | 21,752 | 143.56 k | 2,651,475 |
19 Mar 24 | Steve Elms | Common Stock | Sell | Dispose S | Yes | No | 6.08 | 411,829 | 2.50 mm | 2,115,671 |
18 Mar 24 | Steve Elms | Common Stock | Sell | Dispose S | Yes | No | 6.01 | 49,887 | 299.82 k | 2,527,500 |
15 Mar 24 | Steve Elms | Common Stock | Sell | Dispose S | Yes | No | 6.01 | 183,008 | 1.10 mm | 2,577,387 |
14 Mar 24 | Steve Elms | Common Stock | Sell | Dispose S | Yes | No | 6.05 | 448,276 | 2.71 mm | 2,760,395 |
13 Mar 24 | Steve Elms | Common Stock | Sell | Dispose S | Yes | No | 6.21 | 407,000 | 2.53 mm | 3,208,671 |
News
Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study
11 Apr 24
A Closer Look at 6 Analyst Recommendations For ADMA Biologics
26 Mar 24
ADMA Biologics Reports FDA Approvals Of Extended Room Temperature Storage Conditions For ASCENIV & BIVIGAM
11 Mar 24
Piper Sandler Maintains Buy on ADMA Biologics, Raises Price Target to $10
1 Mar 24
Cantor Fitzgerald Maintains Overweight on ADMA Biologics, Raises Price Target to $8
29 Feb 24